Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Vaccine

• Publication date

  2006-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2005.11.011PMID 16325969
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant DNA-derived leishmania proteins: from the laboratory to the field.

  2005cited by this paper
• Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.

  2004cited by this paper
• Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population.

  2004cited by this paper
• Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections

  2003cited by this paper
• The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms

  2003cited by this paper
• Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis.

  2003cited by this paper
• Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.

  2003cited by this paper
• Clan CD cysteine peptidases of parasitic protozoa.

  2003cited by this paper
• Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine

  2003cited by this paper
• IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection.

  2002cited by this paper
• Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation.

  2002cited by this paper
• Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).

  2002cited by this paper
• Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4+and CD8+T Cell Responses and Protection Against Leishmania major Infection

  2002cited by this paper
• Leishmania donovani p36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis

  2001cited by this paper
• Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.

  2001cited by this paper
• Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters.

  2001cited by this paper
• Leishmaniasis: Current Status of Vaccine Development

  2001cited by this paper
• A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.

  2001cited by this paper
• Immunization with a Recombinant Stage-Regulated Surface Protein from Leishmania donovani Induces Protection Against Visceral Leishmaniasis1

  2000cited by this paper
• BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice.

  2000cited by this paper
• Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

  2000cited by this paper
• A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

  2000cited by this paper
• The host response to Leishmania infection.

  2000cited by this paper
• T-cell response in human leishmaniasis.

  1999cited by this paper
• CpG motifs as immune adjuvants.

  1999cited by this paper
• Immunostimulatory DNA as an Adjuvant in Vaccination against Leishmania major

  1999cited by this paper
• Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions.

  1998cited by this paper
• The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994.

  1996cited by this paper
• CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.

  1996cited by this paper
• Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice

  1995cited by this paper
• Immunology of leishmaniasis.

  1993cited by this paper
• Imidazole‐SDS‐Zn reverse staining of proteins in gels containing or not SDS and microsequence of individual unmodified electroblotted proteins

  1992cited by this paper
• Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis.

  1991cited by this paper

• Pentamidine-Functionalized Polycaprolactone Nanofibers Produced by Solution Blow Spinning for Controlled Release in Cutaneous Leishmaniasis Treatment

  2026cites this paper
• Candidate antigens for serological testing (ELISA) and diagnosis of canine visceral leishmaniasis

  2025cites this paper
• Diagnostic potential of GLP recombinant antigens in whole blood assays for Leishmania infantum infection

  2025cites this paper
• Evaluation of MHC class I-binding peptides from Leishmania spp. for vaccine development against visceral leishmaniasis.

  2025cites this paper
• New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine

  2024cites this paper
• An update on recombinant vaccines against leishmaniasis

  2024cites this paper
• Detection of immune response cells, blood indicators, and enzymatic antioxidants in individuals with cutaneous leishmaniasis

  2023cites this paper
• Vaccination in Leishmaniasis: A Review Article

  2021cites this paper
• Immunogenicity and potential protection of DNA vaccine of Leishmania martiniquensis against Leishmania infection in mice.

  2021influential citation
• Immunotherapy in treatment of leishmaniasis.

  2021cites this paper
• Development of a successful vaccine for leishmaniasis: possibilities and challenges

  2021cites this paper
• Development of the Antileishmanial Vaccine.

  2021cites this paper
• Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB-CTE Antigens against Visceral Leishmaniasis in Syrian Hamster as Preliminary Study

  2020cites this paper
• Cloning and Expression of Truncated Haemoglobin Receptor of Leishmania tropica as a Vaccine Candidate

  2020cites this paper
• Genetically modified live attenuated vaccine: a potential strategy to combat visceral leishmaniasis.

  2020cites this paper
• A Canine-Directed Chimeric Multi-Epitope Vaccine Induced Protective Immune Responses in BALB/c Mice Infected with Leishmania infantum

  2020cites this paper
• Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.

  2019cites this paper
• A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice

  2019cites this paper
• Visceral leishmaniasis: A novel nuclear envelope protein ‘nucleoporins‐93 (NUP‐93)’ from Leishmania donovani prompts macrophage signaling for T‐cell activation towards host protective immune response

  2019cites this paper
• Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments

  2019cites this paper
• Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis

  2018cites this paper
• Enhancement of Th1 immune response against Leishmania cysteine peptidase A, B by PLGA nanoparticle

  2018cites this paper
• Induction of Immune Responses by DNA Vaccines Formulated with Dendrimer and Poly (Methyl Methacrylate) (PMMA) Nano-Adjuvants in BALB/c Mice Infected with Leishmania major

  2018cites this paper
• A defined subunit vaccine that protects against vector-borne visceral leishmaniasis

  2017cites this paper
• Metotrexát tartalmú peptid-biokonjugátumok szintézise és jellemzése

  2017cites this paper
• Co-factor-independent phosphoglycerate mutase of Leishmania donovani modulates macrophage signalling and promotes T-cell repertoires bearing epitopes for both MHC-I and MHC-II

  2017cites this paper
• Chemotherapeutics of visceral leishmaniasis: present and future developments

  2017cites this paper
• Vaccine Development for Leishmaniasis

  2016cites this paper
• Recent developments and future prospects in the treatment of visceral leishmaniasis

  2016cites this paper
• Vacunas contra Leishmania

  2016cites this paper
• Post-Genomics and Vaccine Improvement for Leishmania

  2016cites this paper
• Studies on Immunological Responses to Parasite Surface Antigen as a Potential Vaccine Candidate against Human Leishmaniasis and Estimation of Asymptomatic Leishmania Infection in the Endemic Areas

  2016cites this paper
• Overview of dendritic cell‐based vaccine development for leishmaniasis

  2016cites this paper
• The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine

  2016cites this paper
• Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major

  2016cites this paper
• Vaccines for visceral leishmaniasis: A review.

  2015cites this paper
• Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.

  2015cites this paper
• Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis

  2015cites this paper
• Immunomodulatory Effects of Four Leishmania infantum Potentially Excreted/Secreted Proteins on Human Dendritic Cells Differentiation and Maturation

  2015cites this paper
• From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE

  2015cites this paper
• Strategies to Overcome Antileishmanial Drugs Unresponsiveness

  2014cites this paper
• Survey Protein Vaccine Formulated with Montanide ISA 70 Effects following Immunization and after Challenge with Leishmania major

  2014cites this paper
• Leishmanioses do continente americano

  2014cites this paper
• Cutaneous Leishmaniasis in Middle East and North Africa

  2014cites this paper
• Synthesis and Biological Evaluation of a Library of Polyacetylene Compounds based on an Antiprotozoal Natural Product from Cussonia zimmermannii

  2014cites this paper
• Vaccines to prevent leishmaniasis

  2014cites this paper
• Identifying vaccine targets for anti-leishmanial vaccine development

  2014cites this paper
• Biomarkers of Safety and Immune Protection for Genetically Modified Live Attenuated Leishmania Vaccines Against Visceral Leishmaniasis – Discovery and Implications

  2014cites this paper
• Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines

  2014cites this paper
• The Emergence of Defined Subunit Vaccines for the Prevention of Leishmaniasis

  2014cites this paper
• Current Status and Future Challenges for the Development of Genetically Altered Live Attenuated Leishmania Vaccines

  2014cites this paper
• Modular Multiantigen T Cell Epitope–Enriched DNA Vaccine Against Human Leishmaniasis

  2014cites this paper
• Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches

  2014cites this paper
• Investigation of the molecular adjuvant potential of Trypanosoma congolense BiP/HSP70 using congopain as model antigen.

  2013influential citation
• Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral Leishmaniasis

  2013cites this paper
• Case study for a vaccine against leishmaniasis.

  2013cites this paper
• Rajan Guha Protects Against Visceral Leishmaniasis Encoding DNA − Hemoglobin Receptor Leishmania Vaccination with

  2013cites this paper
• Leishmania CPA, CPB and CPC cysteine proteases

  2013cites this paper
• Cationic solid–lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice

  2013cites this paper
• Vaccination with Leishmania Hemoglobin Receptor–Encoding DNA Protects Against Visceral Leishmaniasis

  2013cites this paper
• Leishmaniasis: recombinant DNA vaccination and different approaches for vaccine development

  2013cites this paper
• Vaccination as a Control Measure

  2013cites this paper
• Head-to-Head Comparison of Three Vaccination Strategies Based on DNA and Raw Insect-Derived Recombinant Proteins against Leishmania

  2012cites this paper
• Leishmania donovani Triose Phosphate Isomerase: A Potential Vaccine Target against Visceral Leishmaniasis

  2012cites this paper
• The development and clinical evaluation of second-generation leishmaniasis vaccines.

  2012cites this paper
• Vaccination with L. infantum chagasi Nucleosomal Histones Confers Protection against New World Cutaneous Leishmaniasis Caused by Leishmania braziliensis

  2012cites this paper
• Vaccine Development Against Leishmania donovani

  2012influential citation
• Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.

  2012cites this paper
• Cloning of a Recombinant Plasmid Encoding Thiol-Specific Antioxidant Antigen ( TSA ) Gene of Leishmania major and Expression in the Chinese Hamster Ovary Cell Line

  2012cites this paper
• Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems

  2012cites this paper
• The Leishmania TDR1 family-related gene: functional studies and evaluation of TDR1 recombinant protein as a vaccine agaist leishmaniasis

  2012cites this paper
• Cloning of a Recombinant Plasmid Encoding Thiol-Specific Antioxidant Antigen (TSA) Gene of Leishmania majorand Expression in the Chinese Hamster Ovary Cell Line.

  2012cites this paper
• Cysteine proteases as potential antigens in antiparasitic DNA vaccines.

  2011cites this paper
• Development of Vaccines against Visceral Leishmaniasis

  2011cites this paper
• Co‐administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice

  2011cites this paper
• Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection.

  2011cites this paper
• Potency, Efficacy and Durability of DNA/DNA, DNA/Protein and Protein/Protein Based Vaccination Using gp63 Against Leishmania donovani in BALB/c Mice

  2011cites this paper
• Cysteine peptidases of kinetoplastid parasites.

  2011cites this paper
• KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral Leishmaniasis

  2011influential citation
• Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae

  2011cites this paper
• Vaccine candidates for leishmaniasis: a review.

  2011cites this paper
• Partial protective responses induced by a recombinant cysteine proteinase from Leishmania (Leishmania) amazonensis in a murine model of cutaneous leishmaniasis.

  2010cites this paper
• Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine.

  2010cites this paper
• Vaccins polyprotéiques recombinants destinés au traitement et au diagnostic de la leishmaniose

  2009cites this paper
• Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs.

  2009cites this paper
• Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

  2009cites this paper
• Kinetoplastid papain-like cysteine peptidases.

  2009cites this paper
• Identification of Novel Leishmania donovani Antigens that Help Define Correlates of Vaccine-Mediated Protection in Visceral Leishmaniasis

  2009cites this paper
• Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine.

  2009cites this paper
• Vaccines and vaccination strategies against human cutaneous leishmaniasis

  2009cites this paper
• DNA Immunization as an Efficient Strategy for Vaccination

  2009cites this paper
• Searching genes encoding Leishmania antigens for diagnosis and protection

  2009cites this paper
• Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.

  2008cites this paper
• Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.

  2008cites this paper
• Recent developments in leishmaniasis vaccine delivery systems

  2008cites this paper
• Immunogenicity of HSP70 , KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis

  2008cites this paper
• Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis.

  2008cites this paper
• Cutaneous leishmaniasis: progress towards a vaccine

  2008cites this paper
• A heterologous prime/boost immunisation strategy protects against virulent E. ruminantium Welgevonden needle challenge but not against tick challenge.

  2008cites this paper
• Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells.

  2008cites this paper